(Q38255585)

1 September 2017

1 reference

title

Modified allergens and their potential to treat allergic disease (English)

1 reference

1 September 2017

2

Ronald van Ree

1 reference

1 September 2017

Laurian Jongejan

1

1 reference

1 September 2017

language of work or name

1 reference

1 December 2014

1 reference

Current Allergy and Asthma Reports

1 September 2017

published in

1 reference

1 September 2017

volume

14

1 reference

1 September 2017

issue

12

1 reference

1 September 2017

page(s)

478

1 reference

https://scigraph.springernature.com/pub.10.1007/s11882-014-0478-9

1 September 2017

exact match

0 references

cites work

Patient-reported outcomes and quality-of-life questionnaires in the assessment of rhinoconjunctivitis in childhood.

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Prevalence of allergic rhinitis in china

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Prevalence of allergic diseases of schoolchildren in central taiwan. From ISAAC surveys 5 years apart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

The epidemiology of food allergy in Europe: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

The prevalence of plant food allergies: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Long-term clinical efficacy of grass-pollen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Combination peptide immunotherapy based on T-cell epitope mapping reduces allergen-specific IgE and eosinophilia in allergic airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

100 years of hyposensitization: history of allergen-specific immunotherapy (ASIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Local nasal specific immunotherapy for allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

New routes for allergen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Epicutaneous Immunotherapy for Aeroallergen and Food Allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Efficacy and safety of allergen-specific immunotherapy in rhinitis, rhinoconjunctivitis, and bee/wasp venom allergies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Treatment of peanut allergy with rush immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Sublingual vs oral immunotherapy for food allergy: identifying the right approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Safety of engineered allergen-specific immunotherapy vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

FAST: towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Characterization and crystallization of a recombinant IgE Fab fragment in complex with the bovine beta-lactoglobulin allergen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or T(H)2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalv

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Adjuvants for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Comparison of allergen immunotherapy practice patterns in the United States and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Aluminium in allergen-specific subcutaneous immunotherapy--a German perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Frontiers of transcutaneous vaccination systems: novel technologies and devices for vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Heat shock proteins: stimulators of innate and acquired immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

1alpha,25-dihydroxyvitamin D3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for IL-10 and TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

25-hydroxvitamin D3 promotes the long-term effect of specific immunotherapy in a murine allergy model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Vitamin D as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust mite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Intradermal application of vitamin D3 increases migration of CD14+ dermal dendritic cells and promotes the development of Foxp3+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

PROPHYLACTIC INOCULATION AGAINST HAY FEVER

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

Covalent Coupling of Vitamin D3 to the Major Cat Allergen Fel d 1 Improves the Effects of Allergen-Specific Immunotherapy in a Mouse Model for Cat Allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11882-014-0478-9

The prevalence of food allergy: A meta-analysis

21 January 2018

1 reference

12 December 2020

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses

1 reference

12 December 2020

Vitamin D and its role in allergic disease

1 reference

12 December 2020

Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial

1 reference

12 December 2020

Immunotherapy with oligomannose-coated liposomes ameliorates allergic symptoms in a murine food allergy model

1 reference

12 December 2020

Nanoparticulate adjuvants and delivery systems for allergen immunotherapy

1 reference

12 December 2020

Alum adjuvanticity: unraveling a century old mystery

1 reference

12 December 2020

Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy

1 reference

12 December 2020

Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity

1 reference

12 December 2020

Symptomatic relief after grass nasal immunotherapy: lasting efficacy after 4-5 years

1 reference

12 December 2020

Long-term follow-up of nasal immunotherapy to Parietaria: clinical and local immunological effects

1 reference

12 December 2020

Time trends in the prevalence of asthma and allergy among 6-7-year-old children. Results from ISAAC phase I and III studies in Kaunas, Lithuania

1 reference

12 December 2020

US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up

1 reference

12 December 2020

Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells

1 reference

12 December 2020

Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen

1 reference

12 December 2020

Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study

1 reference

12 December 2020

Reply: To PMID 24035151

1 reference

12 December 2020

The future of antigen-specific immunotherapy of allergy

1 reference

12 December 2020

Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract

1 reference

12 December 2020

Intralymphatic immunotherapy: time interval between injections is essential

1 reference

12 December 2020

10.1007/S11882-014-0478-9

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

1043150316

0 references

1 reference